View in EDS PDF Full Text

Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival.

Saved in:
Bibliographic Details
Title: Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival.
Authors: De Leo S; Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy., Di Stefano M; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy., Persani L; Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy.; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy., Fugazzola L; Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy. laura.fugazzola@unimi.it.; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy. laura.fugazzola@unimi.it., Colombo C; Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Source: Endocrine [Endocrine] 2021 May; Vol. 72 (2), pp. 462-469. Date of Electronic Publication: 2020 Sep 03.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 9434444 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-0100 (Electronic) Linking ISSN: 1355008X NLM ISO Abbreviation: Endocrine Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32885329
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22De+Leo+S%22">De Leo S</searchLink>; Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Di+Stefano+M%22">Di Stefano M</searchLink>; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Persani+L%22">Persani L</searchLink>; Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy.; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Fugazzola+L%22">Fugazzola L</searchLink>; Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy. laura.fugazzola@unimi.it.; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy. laura.fugazzola@unimi.it.<br /><searchLink fieldCode="AU" term="%22Colombo+C%22">Colombo C</searchLink>; Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229434444%22">Endocrine</searchLink> [Endocrine] 2021 May; Vol. 72 (2), pp. 462-469. <i>Date of Electronic Publication: </i>2020 Sep 03.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9434444 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1559-0100 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%221355008X%22">1355008X </searchLink><i>NLM ISO Abbreviation: </i>Endocrine <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32885329
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s12020-020-02477-0
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 462
    Titles:
      – TitleFull: Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: De Leo S
      – PersonEntity:
          Name:
            NameFull: Di Stefano M
      – PersonEntity:
          Name:
            NameFull: Persani L
      – PersonEntity:
          Name:
            NameFull: Fugazzola L
      – PersonEntity:
          Name:
            NameFull: Colombo C
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2021 May
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1559-0100
          Numbering:
            – Type: volume
              Value: 72
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Endocrine
              Type: main
ResultId 1